Drug Trial Radar · NCT07931703
Safety, Tolerability and Efficacy of RGH-202 in Social Anxiety Disorder (STAGE)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Nov 12, 2026
Primary completion
Feb 13, 2028
Study completion Feb 13, 2028
Sponsor
- Lead sponsor
- Gedeon Richter Plc.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this trial is to see if the investigational product, called RGH-202, is safe and well tolerated, and can help people with social anxiety disorder. The main questions this study aims to answer are: * Is RGH-202 safe and well tolerated in adults with social anxiety disorder? * Does RGH-202 reduce symptoms of social anxiety disorder compared with placebo? RGH-202 will be compared with a placebo (a product that does not contain any active ingredients) to determine whether the investigational medicine may be an effective treatment for SAD. Participants will have an equal chance of receiving RGH-202 or the placebo taken for 6 weeks. Participants will attend regular clinic visits for safety assessments, study evaluations and complete questionnaires related to their social anxiety symptoms.
Conditions
- Social Anxiety Disorder
Interventions
RGH-202Drug
Oral capsule dosage form applied once daily for 42 days
PlaceboDrug
Oral capsule dosage form applied once daily for 42 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse eventsTime frame: From enrollment to the end of follow-up at 8 week
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Leading Edge Research LA, LLC
Encino, California
Clinical Neuroscience Solutions, LLC
Jacksonville, Florida
Clinical Neuroscience Solutions, LLC
Orlando, Florida
Redbird Research LLC.
Las Vegas, Nevada
Integrative Clinical Trials, LLC
Brooklyn, New York
New Hope Clinical Research Inc.
Charlotte, North Carolina
Clinical Neuroscience Solutions, LLC
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.